Pharmaceutical Preparations · Z4 · CIK 1401040
Clinical-stage biopharmaceutical company developing therapies for severe ischemic disease and acute pancreatitis
Comparable business profile · signals at a glance
In the 90 days to Nov 25, 2025: 1 insider bought $7.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 25, 2025 | Trill AbTenPercentOwner | Buy | 73,099 | $8.57 | $626K |
| Nov 24, 2025 | Trill AbTenPercentOwner | Buy | 40,253 | $7.89 | $318K |
| Nov 21, 2025 | Trill AbTenPercentOwner | Buy | 208,872 | $7.41 | $1.5M |
| Nov 20, 2025 | Trill AbTenPercentOwner | Buy | 128,426 | $7.41 | $952K |
| Nov 19, 2025 | Trill AbTenPercentOwner | Buy | 240,352 | $7.21 | $1.7M |
| Nov 18, 2025 | Trill AbTenPercentOwner | Buy | 182,882 | $6.75 | $1.2M |
| Nov 17, 2025 | Trill AbTenPercentOwner | Buy | 187,393 | $6.52 | $1.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.